The Influence of Antidepressants on the Immune System

Łukasz P. Szalach · Katarzyna A. Lisowska · Wiesław J. Cubała

Abstract
Depression is one of the most frequently diagnosed condition in psychiatry. Despite the availability of many preparations, over 30% of treated patients do not achieve remission. Recently the emphasis is put on the contribution of the body’s inflammatory response as one of the causes of depression. The interactions between nervous and immune systems are the main issue addressed by psychoneuroimmunology. In patients suffering from depression changes in the plasma concentrations of cytokines and in the number and level of activation of immune cells has been found. Attention is paid to the high levels of pro-inflammatory cytokines, the prevalence of Th1 responses to Th2, weakening of NK cell cytotoxicity and changes in lymphocyte proliferation and apoptosis. A number of studies focus on influence of antidepressants and non-standard methods of depression treatment, such as ketamine infusion, on patients’ immunology. Many of them seem to regulate the immune responses. The study results encourage to look for new ways to treat depression with immunomodulatory drugs. In this article authors present the current knowledge about immune system changes accompanying depression as well as the study results showing the influence of drugs on the immune system, especially in the context of reducing the symptoms of depression.

Keywords Depression · Antidepressants · Lymphocytes · Cytokines · Proliferation · Apoptosis

Introduction
Depression is a condition that occurs in the course of many psychiatric disorders. It can be caused by various factors and have varying severity and duration. Using the term “depression” we usually mean a major depressive episode during the recurrent depressive disorder or major depressive disorder. A depressive episode can be also a component of bipolar disease in which depressive episodes are intertwined with manic episodes. Typical symptoms of depression include depressive mood, anhedonia, sleep changes, psychomotor retardation, decreased appetite and libido, weight loss, feeling of worthlessness as well as suicidal thoughts and suicide attempts, although not all of them must be present for the diagnosis of depression. To meet the criteria of a depressive episode (both according to ICD-10 and DSM-V), the symptoms should last for a minimum of 2 weeks for most of the day. These symptoms may be accompanied by anxiety and psychotic symptoms, such as delusions (most often of guilt or sin) and hallucinations (American Psychiatric Association 2013; World Health Organization 2016).

Depression as a syndrome is the body’s response to a variety of genetic, psychological, environmental and biological factors (Murawiec and Wierzbinski 2016). Nowadays attention is paid to the role of inflammation resulting from the activation of the immune system in the course of depression, especially in its drug-resistant form. Also, it has been proven that antidepressants modulate immune responses thus affecting the activation, proliferation and survival of leukocytes.

Psychoneuroimmunology is a field of study based on the concept of mutual interaction between nervous, endocrine and immune systems taking into account the influence of mental state on patient’s immunity (Pariante 2015) (Fig. 1). It has been scientifically proven that the function of lymphatic organs and cells of the immune system can be regulated by the nervous system with the help of hormones, secreted mainly by the pituitary gland, and by neurotransmitters, among others, noradrenaline, acetylcholine released directly from the axons of cells of the autonomic nervous system (Talbot et al. 2016). Lymphocytes and macrophages
are also known to express on their surface a number of receptors for neurotransmitters like noradrenaline, acetylcholine, dopamine, serotonin, gamma-aminobutyric acid, endorphins and hormones such as corticotropin (CRH), allowing them to respond to signals sent by nervous system (Rybakowski 2002). In response to the stimulation of receptors with the aforementioned substances, a number of processes in immune cells are activated, including the production of cytokines secreted into the bloodstream allowing their systemic action, and hormones, mainly pituitary, such as corticotropin (ACTH), thyrotropin (TSH) or endorphins, mainly acting locally as auto- and paracrine hormones (Pállinger and Csaba 2008).

Cytokines of immune cells are secreted both systemically and locally within the central nervous system (CNS). Some of them, such as interleukin (IL)-6, delivered by the bloodstream can pass through the blood–brain barrier (BBB) (Banks et al. 1994). They also affect indirectly the inflammatory process within the central nervous system by cerebral endothelium stimulation for the expression of adhesion molecules with co-stimulatory properties, such as intercellular adhesion molecule 1 and vascular cell adhesion protein 1, and the major histocompatibility complex class II with interferon (IFN)-γ, so that T lymphocytes specific for the brain antigens may be activated to cross BBB and stimulate the inflammation. Additionally, both neurons and glial cells also can produce and secrete cytokines locally (Stokłosa 2017).

Knowledge about mechanisms of anti-inflammatory and pro-inflammatory processes, activity of immune cells and their mutual relations with the nervous and endocrine systems may help to understand the role of immune system in affective disorders. The purpose of this article is to show that, in addition to the classical effects on the neurotransmitter system in the brain, antidepressants can also modulate the immune responses in patients suffering from depressive disorders, and thus contribute to clinical state improvement in patients during anti-depressive treatment.

**Immune System Dysregulation in Depression**

Regulation of immune system activity and chronic inflammation seems to play an important role in the pathogenesis of depression. One of the basic and best-studied mechanisms of interaction between nervous, endocrine and immune systems is their mutual influence during chronic stress or chronic inflammation accompanying some of the patients presenting features of the depressive syndrome.

Stress induces the transmission of nerve signals from the cerebral cortex to the hypothalamus where it stimulates the secretion of CRH, then ACTH by the pituitary gland which results in the release of glucocorticoids from adrenal cortex. Glucocorticoids act in immunosuppressive manner on the immune cells through the inhibition of cytokines production essential for the development of the inflammation, e.g., IL-1, IL-6, tumor necrosis factor (TNF)-α, IL-2 or IFN-γ, simultaneously reducing the T lymphocytes activity (Oppong and Cato 2015). They also favor the recruitment of transcription factors to promoters of genes encoding proteins with anti-inflammatory properties, such as IL-10, I kB, annexin 1 or α-2-microglobulin (Oppong and Cato 2015).

The CNS can also inhibit the immune responses during chronic inflammation; when locally activated immune cells secrete into the blood stream a number of pro-inflammatory
cytokines (IL-1, IL-6, TNF-α), the hypothalamic–pituitary–adrenal (HPA) axis is secondarily stimulated which consequently leads to the secretion of CRH and ACTH. Again, this results in suppression of the immune response through adrenocortical hormones (Hilal-Dandan and Brunton 2014). Unfortunately, in the situation of depressive episode, the immunosuppressive effect of the HPA axis seems to be insufficient to reduce inflammation associated with depression, which may be result of steroid resistance of immune cells or decrease in the threshold of hypothalamic sensitivity to pro-inflammatory cytokines secreted by these cells (Hilal-Dandan and Brunton 2014) (Fig. 2).

The inflammatory hypothesis of depression has been described and confirmed in a number of scientific studies. Elevated concentration of cortisol was observed in the blood of patients with the first major depressive episode diagnosed at an early age (Cubala and Landowski 2014, Cubala et al. 2016). It has been demonstrated that concentrations of pro-inflammatory cytokines are elevated in the serum of patients suffering from depressive disorders, mainly IL-1, IL-6, IFN-γ and TNF-α, which has been confirmed in several meta-analyses (Dowlati et al. 2010, Haapakoski et al. 2015, Schmidt et al. 2014a) (Fig. 3). The increase in the level of pro-inflammatory cytokines was accompanied by increased plasma concentrations of granulocyte–macrophage colony-stimulating factor (Schmidt et al. 2014a) and monocyte chemoattractant protein 1 (Kiraly et al. 2017). Pro-inflammatory cytokines are mainly produced by type 1 T helper (Th1) cells which together with macrophages, dendritic cells and cytotoxic T cells are involved in a cell-mediated immunity essential for the elimination of the intracellular pathogens. Elevated concentrations of other cytokines, such as IL-5, IL-7, IL-8, IL-10, IL-12, IL-13 (Schmidt et al. 2014a) have also been reported in some studies. These cytokines are involved in the development of humoral response against extracellular pathogens supported by Th2 cells. Increased activation of inflammasome NLRP3 (a multi-oligomer responsible for the activation of inflammatory responses) in peripheral blood mononuclear cells (PBMCs) of patients suffering from the depression has been described as well (Alcocer-Gómez et al. 2017). It is also known that IFN-α exogenously administered to treat chronic viral hepatitis C can cause transient symptoms of depression (Bonaccorso et al. 2002). In patients vaccinated against Salmonella typhi depressive symptoms occurred after vaccine administration and were positively correlated with elevated levels of IL-6 (Wright et al. 2005).

Changes of the immune system in patients suffering from depression are also noticeable in the number and ratio of leukocyte populations. An increase in the number of cells involved in the inborn immune responses, i.e., monocytes, macrophages and neutrophils (Demir et al. 2015), as well as increased production of reactive oxygen species (ROS) has been reported (Wei et al. 2015). In turn, a reduction in the number of NK cells, which are responsible for natural cytotoxicity was observed (Patias et al. 2018), accompanied by a simultaneous decrease in their activation compared to healthy people (Stoklosa 2017, Zorrilla et al. 2001). Some authors reported an increase in the ratio of CD4+ T (Th) cells to CD8+ cytotoxic (Tc) T lymphocytes (Di Rosso et al. 2016; Zorrilla et al. 2001). In addition, T lymphocytes of depressed patients presented significantly reduced expression of chemokine receptors CXCR3 and CCR6 (Patias et al. 2018), which play an important role in the recruitment of leukocytes to places where the inflammatory process is present. Additionally, an increase in the percentage of CD25+...
cells (activated T cells) (Müller et al. 1993; Patas et al. 2018) with the accompanying decrease in the total number of regulatory T lymphocytes (Treg) (Toben and Baune 2015), which are responsible for suppression of immune responses, within CD4+ T cell population have also been observed. Some authors demonstrated that lymphocytes of depressed patients were also characterized by decreased response to mitogen stimulation in vitro (Darko et al. 1989; Kronfol et al. 1986; Toben and Baune 2015), while study of Schleifer et al. (1999) reported the opposite effect. Moreover, PBMCs of patients were also more prone to apoptosis (programmed cell death) compared to healthy people (Ivanova et al. 2007).

Even though there are animal and human studies suggesting that there can be stress-related B lymphocyte decrements...
due to high levels of glucocorticoids, both the number of B cells and the level of antibodies in the serum of patients suffering from depression seem to be comparable to those observed in healthy persons (Dubois et al. 2016). Some authors suggest that autoantibodies, such as anti-ribosomal-P and anti-N-methyl-D-aspartate receptor antibodies, which are present in patients suffering from autoimmune diseases such as systemic lupus erythematosus might contribute to pathophysiolo gy of depression in that group (Isseme et al. 2014; Postal and Appenzeller 2015). Recently, Ahmetspahic et al. (2018) demonstrated that frequencies of naive B cells as well as regulatory B cells are reduced in severely depressed patients as compared to healthy donors or mildly to moderately depressed patients, which suggests that the humoral response could play a role in the development of inflammation in the course of depression. However, there are still only a few articles about disorder of the humoral response in patients suffering from depression and this topic requires further research.

The changes in the immune system described above may contribute to the development of depression in various ways (Schmidt et al. 2014a). The pro-inflammatory cytokines such as IFN-γ, IL-1 or IL-6 affect the HPA axis by stimulating the secretion of CRH and increasing steroid resistance (Cubala and Landowski 2014), which secondarily stimulates the organism to produce more immunosuppressive glucocorticoids (Pariante and Lightman 2008). Also, cytokines induce production of inducible nitric oxide synthase, which leads to increased synthesis of ROS that cause protein and DNA damage that result in neurotoxicity and neurodegeneration (Inserra et al. 2018). Moreover, NO decreases norepinephrine production (Karolewicz et al. 2001) and inhibits the dopamine transporter, which decreases the availability of inter-synaptic dopamine (Sandor et al. 1995).

The most known neurobiological theory explaining mechanism of depression is monoamine theory, especially the serotonin hypothesis. The serotonin hypothesis of depression postulates that a reduction in serotonin levels may cause depression (Cowen and Browning 2015). Indeed, most of the widely used anti-depressive medications in the medical practice focus on increasing serotonin level in the synaptic cleft, such as tricyclic antidepressants (TCA), selective serotonin/serotonin and noradrenaline reuptake inhibitors (SSRI and SNRI) as well as antiepileptic drugs (e.g., lamotrigine, valproic acid) and antipsychotics (including quetiapine, olanzapine, amisulpride). In addition to the known mechanism of action of these drugs on neurotransmitter transporters and pre- and post-synaptic receptors located on the neuronal membrane (serotonergic, dopaminergic, adrenergic), it is considered that they may have immunomodulatory properties which can contribute to achieving a therapeutic effect in patients with depression through this mechanism as well.

Currently, as mentioned above, the main drugs used for pharmacotherapy of depression are drugs that affect the level of neurotransmitters in the synaptic cleft, such as tri-cyclic antidepressants (TCA), selective serotonin/serotonin and noradrenaline reuptake inhibitors (SSRI and SNRI) as well as antiepileptic drugs (e.g., lamotrigine, valproic acid) and antipsychotics (including quetiapine, olanzapine, amisulpride). In addition to the known mechanism of action of these drugs on neurotransmitter transporters and pre- and post-synaptic receptors located on the neuronal membrane (serotonergic, dopaminergic, adrenergic), it is considered that they may have immunomodulatory properties which can contribute to achieving a therapeutic effect in patients with depression through this mechanism as well.

A meta-analysis by Strawbridge based on 35 clinical trials performed in over 20 years has shown that in patients suffering from unipolar depression, who have responded to widely understood antidepressant treatment, serum level of TNF-α and IL-6 significantly decreased (Fig. 3) while no significant change in C-reactive peptide concentration before and after treatment was observed (Strawbridge et al. 2015). Other meta-analysis involving the examination of 22 studies showed that the level of IL-1β in patients’ serum significantly decreased after pharmacotherapy (SSRI, SNRI or TCA), IL-6 level decreased slightly in patients receiving SSRI, while TNF-α levels did not change significantly regardless of the taken medicine (Hannestad et al. 2011).

In study of Dahl et al. (2014), which measured peripheral blood cytokine levels before and after 12-week antidepressant therapy in 50 patients, a significant reduction in the level of cytokines IL-6, IL-7, IL-8, IL-10, G-CSF, IFN-γ and IL-1 receptor antagonist was reported. Importantly, the drop in the levels of these cytokines was seen only in patients
who demonstrated clinical response to treatment (Dahl et al. 2014). In another randomized trial a decrease in the concentration of pro-inflammatory cytokines was also observed in 73 patients who received sertraline (some of the patient received also transcranial magnetic stimulation therapy). Unfortunately, in this study the decrease also occurred in people taking placebo and was not related to the antidepressant effect (Brunoni et al. 2014). In another study, in which the level of soluble TNF receptor (sTNFR) was measured before and after treatment with sertraline, showed no significant difference in the concentration sTNFR in plasma after sertraline administration (Brunoni et al. 2015).

Antidepressants can influence activity and numbers of immune cells as well but not only that. For example, fluoxetine and mirtazapine have been shown to increase the expression of the serotonin transporter on the surface of T lymphocytes (Peña et al. 2005), which may improve the reuptake of serotonin thus lowering its concentration in the environment of lymphocytes and, consequently, at the same time reduce their ability to proliferate (Ahern 2011). Immunomodulatory properties of fluoxetine have also been reported in animal models and human. In mice treated with fluoxetine a number of T lymphocytes in the peripheral blood was decreased but the CD4+/CD8+ ratio remained unchanged (Di Rosso et al. 2016). In vitro, a decrease in the proliferative activity of T lymphocytes in patients with depression, who were treated fluoxetine, was also observed (Fazzino et al. 2009). In another study, not only the decrease in the concentration of pro-inflammatory cytokines was observed in 16 patients, after 6 weeks of treatment but also an increased number of Treg cells was observed (Grosse et al. 2016; Himmerich et al. 2010). Schleifer et al. (1999), who demonstrated that in patients with depression T cell response to mitogenic stimulation is significantly increased compared to healthy people, also showed that in patients receiving TCA lymphocyte activity significantly decreases. Several studies showed that pharmacotherapy of depression can also increase the number and cytotoxic activity of NK cells (Mizruchin et al. 2015; Park et al. 2015).

Alcocer-Gómez et al. (2017) examined the expression level of genes encoding elements of NLRP3 inflammasome in mononuclear cells taken from patients receiving antidepressants from the SSRI group (paroxetine), SNRI (venlafaxine, desvenlafaxine), TCA (imipramine, amitriptyline) and patients treated with agomelatine or mianserin, were measured. All of these drugs not only significantly decreased the expression of genes but also reduced inflammasome activity, which decreased of plasma concentrations of IL-1β and IL-18 (Alcocer-Gómez et al. 2017). Changes in the concentration of brain-derived neurotrophic factor (BDNF), a factor responsible for the survival of neurons, stimulating the formation of new nerve cells and synapses, with a broadly defined anti-inflammatory properties, were also observed (Papathanassoglou et al. 2015). Increase in patients’ serum BDNF has been demonstrated as soon as 5 weeks of treatment with sertraline and 6 months when venlafaxine was administered (Matrisiciano et al. 2009). Moreover, studies show that the measurement of BDNF in serum may correlate with the level of BDNF in the central nervous system (Klein et al. 2011).

In the recently published work of Pietruczuk et al. (2018) it was demonstrated that T lymphocytes of patients suffering from bipolar disorder treated with lithium or valproate are characterized by decreased proliferative activity and increased susceptibility to apoptosis. The authors also showed that in vitro both drugs have an anti-apoptotic effect but do not affect in any way the ability of lymphocytes to proliferate (Pietruczuk et al. 2018).

Ketamine, an intravenous anesthetic affecting glutamate neurotransmission, which has also been used in the treatment of drug-resistant depression, also modulates the immune response. Presently, there are no studies showing how ketamine can influence the immune system of patients suffering from affective disorders. However, its immunomodulatory effect has been shown in oncological patients and patients in the postoperative period. It seems that low doses of ketamine administered parenterally cause a temporary decrease in TNF-α and IL-6 concentration in the patient’s blood in the postoperative period (Beilin et al. 2007). Studies performed on mononuclear peripheral blood cells collected from oncological patients showed that ketamine may increase the CD4+/CD8+ ratio as well as the percentage of Treg cells (Hou et al. 2016). Meanwhile, studies in healthy subjects have shown that ketamine can inhibit the differentiation of Th2 cells, which are responsible for regulating humoral responses (Gao et al. 2011). It has also been shown that ketamine may exhibit an immunosuppressive effect not only by reducing the pro-inflammatory cytokines synthesis but do not affect in any way the ability of lymphocytes to proliferate (Pietruczuk et al. 2018).

Immunomodulatory Drugs as Antidepressive Treatment?

An additional argument that the treatment of depression may be effective due to the modification of the immune response, is the results of researches carried out with the use of non-steroidal anti-inflammatory drugs (NSAIDs), cytokine inhibitors, polyunsaturated fatty acids or curcumin (Menon and Sudheer 2007). For example, it has been shown that administration of NSAIDs can reduce the symptoms of depression. The cyclooxygenase-2 inhibitor celecoxib turned out to be
particularly effective (Köhler et al. 2014). Etanercept, a soluble TNF-α receptor, also was shown to reduce depressive symptoms (Schmidt et al. 2014b). Patients suffering from depression treated with infliximab, an anti-TNF antibody, for longer period of time, also benefited from the therapy in terms of improving their mental state (Raison et al. 2013). Curcumin, a nutrient present in plants of the ginger family, may also contribute to the reduction of depressive symptoms when supplemented with classic antidepressant treatment (Yu et al. 2015), most likely by inhibiting the production of inflammatory mediators, such as prostaglandins, leukotrienes or nitric oxide and increasing in the concentration of biogenic amines in the brain (Kulkarni et al. 2008).

Raison and colleagues who performed randomized clinical trial with above-mentioned infliximab concluded that TNF antagonism does not have generalized efficacy in treatment-resistant depression but may improve depressive symptoms in patients with high baseline inflammatory biomarkers (e.g., high sensitivity C-reactive protein) (Raison et al. 2013). The meta-analysis of randomized, placebo-controlled trials of omega-3 fatty acid treatment of major depressive disorder demonstrated no significant benefit of omega-3 fatty acid administration (Bloch and Hannestad 2012). Authors also concluded that nearly all of the anti-inflammatory treatment efficacy in major depressive disorder observed in the published literature may be attributable to publication bias caused by heterogeneity of the group including somatic or mental comorbidities and pro-inflammatory markers baseline. Lower methodological quality or trials of shorter duration can also affect the final results. Köhler et al. (2014) in their meta-analysis emphasized that identification of subgroups that could benefit from anti-inflammatory treatment is needed especially since NSAIDs treatment is often accompanied by well-known adverse effects.

Conclusions

According to the assumptions of psychoneuroimmunology, impaired regulation of immune system activity and chronic inflammation may play an important role in the pathogenesis of depression. Furthermore, the results of numerous studies presented in this article show that the mechanism of action of currently used antidepressants is more complex than only their influence on the concentration of neurotransmitters in the synaptic cleft. Unfortunately, the results presented here do not always coincide, which may be the result from many different factors, including the heterogeneity of a group of patients diagnosed with a depression, a various mechanism of action of widely understood antidepressants, different doses of drugs administered, treatment period, co-morbidity, polypharmacotherapy or patients’ age. Nevertheless, it seems that modification of the immune system activity may also improve the mental state of patients suffering from affective disorders, which makes the research on the interaction of the immune and nervous systems particularly interesting.

Compliance with Ethical Standards

Conflict of interest All co-authors reported no biomedical financial interests or potential conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Ahern GP (2011) 5-HT and the immune system. Curr Opin Pharmacol 11:29–33
Ahmetspahic D, Schwarte K, Ambrée O et al (2018) Cell homeostasis in patients with major depressive disorder and normalization of CD5 surface expression on regulatory B cells in treatment responders. J Neuroimmune Pharmacol 13:90–99
Alcocer-Gómez E, Casas-Barquero N, Williams MR et al (2017) Antidepressants induce autophagy dependent-NLRP3-inflammasome inhibition in major depressive disorder. Pharmacol Res 121:114–121
American Psychiatry Association (2013) Major depressive disorder. In: Diagnostic and statistical manual of mental disorders, 5th edn. Washington, DC, https://doi.org/10.1176/appi.books.9780890425596
Banks WA, Kastin AJ, Gutierrez EG (1994) Penetration of interleukin-6 across the murine blood-brain barrier. Neurosci Lett 179:53–56
Beilin B, Rusabov Y, Shapira Y et al (2007) Low-dose ketamine affects immune responses in humans during the early postoperative period. Br J Anaesth 99:522–527
Bloch MH, Hannestad J (2012) Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry 17:1272–1282
Bonaccorso S, Marini V, Biondi M et al (2002) Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 72:237–241
Braun S, Gaza N, Werdehausen R et al (2010) Ketamine induces apoptosis via the mitochondrial pathway in human lymphocytes and neuronal cells. Br J Anaesth 105:347–354
Brunoni AR, Machado-Vieira R, Zarate CA et al (2014) Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial. Psychopharmacology 231:1315–1323
Brunoni AR, Machado-Vieira R, Sampaio-Junior B et al (2015) Plasma levels of soluble TNF receptors 1 and 2 after tDCS and sertraline treatment in major depression: results from the SELECT-TDCS trial. J Affect Disord 185:209–213
Chou YH, Hsieh WC, Chen LC et al (2016) Association between the serotonin transporter and cytokines: implications for the pathophysiology of bipolar disorder. J Affect Disord 191:29–35
Cowen P, Browning M (2015) What has serotonin to do with depression? World Psychiatry 14:158–160
Cubala WJ, Landowski J (2014) C-reactive protein and cortisol in drug-naive patients with short-illness-duration first episode major depressive disorder: possible role of cortisol immunomodulatory action at early stage of the disease. J Affect Disord 152–154:534–537
Cubala WJ, Landowski J, Dziadziszko M et al (2016) Magnesium, C-reactive protein, and cortisol in drug-naive patients with short illness-duration, first episode major depressive disorder: possible immunomodulatory role for magnesium. Magnes Res 29:169–174
Dahl J, Ormstad H, Aass HC et al (2014) The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology 45:77–86
Darko DF, Gillin JC, Risch SC et al (1989) Mitogen-stimulated lymphocyte proliferation and pituitary hormones in major depression. Biol Psychiatry 26:145–155
Demir S, Atli A, Bulut M et al (2015) Neutrophil–lymphocyte ratio in patients with major depressive disorder undergoing no pharmacological therapy. Neuropsychiatr Dis Treat 11:2253–2258
Di Rosso ME, Palumbo ML, Genaro AM (2016) Immunomodulatory effects of fluoxetine: a new potential pharmacological action for a classic antidepressant drug? Pharmacol Res 109:101–107
Dowlati Y, Herrmann N, Swardfager W et al (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 26:145–155
Dubois T, Zdanowicz N, Swardfager W et al (2017) Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Transl Psychiatry 7:e1065
Klein AB, Williamson R, Santini MA et al (2011) Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 14:347–353
Köbler O, Benros ME, Nordenfot M et al (2014) Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71:1381–1391
Kronfol Z, House JD, Silva J et al (1986) Depression, urinary free cortisol excretion and lymphocyte function. Br J Psychiatry 148:70–73
Kulkarni SK, Bhutani MK, Bishnoi M (2008) Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology 201:435–442
Larsen B, Hoff G, Wilhelm W et al (1998) Effect of intravenous anesthetics on spontaneous and endotoxin-stimulated cytokine response in cultured human whole blood. Anesthesiology 89:1218–1227
Malynn S, Campos-Torres A, Moynah P et al (2013) The pro-inflammatory cytokine TNF-α regulates the activity and expression of the serotonin transporter (SERT) in astrocytes. Neurochem Res 38:694–704
Mattrisciano F, Bonaccorso S, Ricciardi A et al (2009) Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatry Res 43:247–254
Menon VP, Sudheer AR (2007) Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 595:105–125
Mizruchin A, Gold I, Krasnov I et al (1999) Comparison of the effects of N-methyl-D-aspartate receptor antagonist on T helper cell differentiation induced by phorbol-myristate-acetate and ionomycin. Cytokine 56:458–465
Grosse L, Carvalho LA, Birkenhager TK et al (2016) Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy. Psychopharmacology 233:1679–1688
Haapakoski R, Mathieu J, Ebmeier KP et al (2015) Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depression. Br J Psychiatr 207:555–562
Hannestad J, Delliagioia N, Bloch M (2011) The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36:2452–2459
Hilal-Dandan R, Brunton LL (2014) Chapter 42: pharmacology of the immune system. In: Goodman and Gilman’s manual of pharmacology and therapeutics, 2nd edn. McGraw-Hill, New York
Himmerich H, Milenovic S, Fulda S et al (2010) Regulatory T cells increased while IL-1β decreased during antidepressant therapy. J Psychiatr Res 44:1052–1057
Hou M, Zhou NB, Li H et al (2016) Morphine and ketamine inhibit immune function of gastric cancer patients by increasing percentage of CD4(+)CD25(+)Foxp3(+) regulatory T cells in vitro. J Surg Res 203:306–312
Inserra A, Mastronardi CA, Rogers G et al (2018) Neuroimmunomodulation in major depressive disorder: focus on caspase 1, inducible nitric oxide synthase, and interferon-gamma. Mol Neurobiol. https://doi.org/10.1007/s12035-018-1359-3
Iseme RA, McEvoy M, Kelly B et al (2014) Autoantibodies and depresion: evidence for a causal link? Neurosci Biobehav Rev 40:62–79
Ivanova SA, Semke VY, Vetlugina TP et al (2007) Signs of apoptosis of immunocompetent cells in patients with depression. Neurosci Behav Physiol 37:527–530
Karolewicz B, Paul IA, Antkiewicz-Michulak L (2001) Effect of NOS inhibitor on forced swim test and neurotransmitters turnover in the mouse brain. Pol J Pharmacol 53:587–596
Kawasaki C, Kawaski T, Ogata M et al (2001) Ketamine isomers suppress superantigen-induced proinflammatory cytokine production in human whole blood. Can J Anesth 48:819–823
Kiraly DD, Horn SR, Van Dam NT et al (2017) Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Transl Psychiatry 7:e1065
Klein AB, Williamson R, Santini MA et al (2011) Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 14:347–353
Köhler O, Benros ME, Nordenfot M et al (2014) Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71:1381–1391
Kronfol Z, House JD, Silva J et al (1986) Depression, urinary free cortisol excretion and lymphocyte function. Br J Psychiatry 148:70–73
Kulkarni SK, Bhutani MK, Bishnoi M (2008) Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology 201:435–442
Larsen B, Hoff G, Wilhelm W et al (1998) Effect of intravenous anesthetics on spontaneous and endotoxin-stimulated cytokine response in cultured human whole blood. Anesthesiology 89:1218–1227
Malynn S, Campos-Torres A, Moynah P et al (2013) The pro-inflammatory cytokine TNF-α regulates the activity and expression of the serotonin transporter (SERT) in astrocytes. Neurochem Res 38:694–704
Mattrisciano F, Bonaccorso S, Ricciardi A et al (2009) Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatry Res 43:247–254
Menon VP, Sudheer AR (2007) Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 595:105–125
Mizranchin A, Gold I, Krasnov I et al (1999) Comparison of the effects of dopaminergic and serotoninergic activity in the CNS on the activity of the immune system. J Neuroimmunol 101:201–204
Müller N, Hofschuster E, Ackenheil M et al (1993) Investigations of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosis. Prog Neuropsychopharmacol Biol Psychiatry 17:713–730
Murawiec S, Wierzbiński P (2016) Depresja. VM Media, Gdańsk
Papathanassoglou ED, Miltiadous P, Karanikola MN (2015) May neuroimmunomodulatory action at early stage of the disease. J Affect Disord 191:29–35
Pállinger É, Csaba G (2008) A hormone map of human immune cells showing the presence of adrenocorticotropic hormone, triiodothyronine and endothphin in immunophenotyped white blood cells. Immunology 123:584–589
Papiathanassoglou ED, Militädsbus P, Karanikola MN (2015) May BDNF be implicated in the exercise-mediated regulation of inflammation? Critical review and synthesis of evidence. Biol Res Nurs 17:521–539
Pariente CM (2015) Psychoneuroimmunology or immunopsychiatry? Lancet Psychiatry 2:197–199
Pariante CM, Lightman SL (2008) The HPA axis in major depression: classical theories and new developments. Trends Neurosci 31:464–468

Park EJ, Lee JH, Jeong DC et al (2015) Natural killer cell activity in patients with major depressive disorder treated with escitalopram. Int Immunopharmacol 28:409–413

Patas K, Willing A, Demiray C et al (2018) T cell phenotype and T cell receptor repertoire in patients with major depressive disorder. Front Immunol 9:291

Peña S, Baccichet E, Urbina M et al (2005) Effect of mirtazapine treatment on serotonin transporter in blood peripheral lymphocytes of major depression patients. Int Immunopharmacol 5:1069–1076

Pietruczuk K, Lisowska KA, Grabowski K et al (2018) Proliferation and apoptosis of T lymphocytes in patients with bipolar disorder. Sci Rep 8:3327

Postal M, Appenzeller S (2015) The importance of cytokines and autoantibodies in depression. Autoimmun Rev 14:30–35

Raison CL, Rutherford RE, Woolwine BJ et al (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70:31–41

Rybakowski J (2002) Neuroimmunologia zaburzeń psychicznych. In: Rybakowski J, Pużyński S, Wciórka J (eds) Psychiatria tom I—podstawy psychiatrii. Elsevier Urban and Partner, Wrocław

Sandor NT, Brassai A, Puskas A et al (1995) Role of nitric oxide in modulating neurotransmitter release from rat striatum. Brain Res Bull 36:483–486

Schleifer SJ, Keller SE, Bartlett JA (1999) Depression and immunity: clinical factors and therapeutic course. Psychiatry Res 85:63–69

Schmidt FM, Lichtblau N, Minkwitz J et al (2014a) Cytokine levels in depressed and non-depressed subjects, and masking effects of obesity. J Psychiatr Res 55:29–34

Schmidt FM, Kirkby KC, Himmerich H (2014b) The TNF-alpha inhibitor etanercept as monotherapy in treatment-resistant depression—report of two cases. Psychiatr Danub 26:288–290

Stahl SM (2013) Chapter 7: antidepressants. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications, 4th edn. Cambridge University Press, New York, pp 285–287

Stokłosa T (2017) Psychoneuroimmunologia. In: Gołąb J, Jakóbisiak M, Lasek W, Stokłosa T (eds) Immunologia, 7th edn. Wydawnictwo Naukowe PWN, Warszawa

Strawbridge R, Arnone D, Danese A et al (2015) Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol 25:1532–1543

Talbot S, Foster SL, Woolf CJ (2016) Neuroimmunity: physiology and pathology. Ann Rev Immunol 34:421–447

Toben C, Baune BT (2015) An act of balance between adaptive and maladaptive immunity in depression: a role for T lymphocytes. J Neuroimmune Pharmacol 10:595–609

Trivedi MH, Rush AJ, Wisniewski SR et al (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28–40

Wei J, Zhang M, Zhou J (2015) Myeloid-derived suppressor cells in major depression patients suppress T-cell responses through the production of reactive oxygen species. Psychiatry Res 228:695–701

World Health Organization (2016) Mood (affective) disorders. In: The ICD-10 classification of mental and behavioral disorders. Geneva, block F30–F39

Wright CE, Strike PC, Brydon L et al (2005) Acute inflammation and negative mood: mediation by cytokine activation. Brain Behav Immun 19:345–350

Yu JJ, Pei LB, Zhang Y et al (2015) Chronic supplementation of curcumin enhances the efficacy of antidepressants in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 35:406–410

Zeng J, Xia S, Zhong W et al (2011) In vitro and in vivo effects of ketamine on generation and function of dendritic cells. J Pharmacol Sci 117:170–179

Zorrilla EP, Luborsky L, McKay JR et al (2001) The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 15:199–226

Zou MH (2015) Tryptophan-kynurenine pathway is dysregulated in inflammation and immune activation. Front Biosci 20:1116–1143

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.